Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years - Boston Scientific ( NYSE:BSX )
Boston Scientific BSX has outperformed the market over the past 10 years by 7.53% on an annualized basis producing an average annual return of 20.65%. Currently, Boston Scientific has a market capitalization of $152.86 billion.
Brokers Suggest Investing in Boston Scientific ( BSX ) : Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Elutia ( ELUT ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, Aug. 14, 2025 at 5 p.m. ETChief Executive Officer - Randy MillsContinue reading ...
Elutia Posts Narrower Loss in Fiscal Q2
Elutia ( NASDAQ:ELUT ) , a medical technology company specializing in biologic products for device protection and surgical reconstruction, released its second-quarter earnings on August 14, 2025, reporting results for the period ended June 30.
Accuray Stock Down as Q4 Earnings Miss Estimates, Revenues Down Y/Y
ARAY stock down after Q4 earnings miss estimates, with product sales hit by tariffs and regional demand softness.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's HSA growth, AI-driven efficiencies, and strong Q1 results fuel optimism despite data security concerns.
CMCT Leasing Surges as NOI Drops in Q2
Creative Media & Community Trust ( NASDAQ:CMCT ) reported fiscal Q2 2025 results on Aug. 12, 2025, highlighting a core funds from operations ( FFO ) loss of $7.2 million and a year-over-year increase of over 55% in leasing activity through July 2025.
RGTI Stock Down Despite Q2 Earnings Top Estimates, Revenues Decline Y/Y
Rigetti posts a narrower adjusted Q2 loss and unveils its largest quantum computer, but revenue declines 41.6% year over year.
CMCT Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, August 13, 2025 at 12 p.m. ETChief Executive Officer - David ThompsonContinue reading ...
Are Medical Stocks Lagging Boston Scientific ( BSX ) This Year?
Here is how Boston Scientific (BSX) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
MDT Stock Trades Cheaper Than Peers Ahead of Q1 Earnings: Time to Buy?
Medtronic trades at a notable discount to peers as Q1 earnings loom, but rising costs and tariffs could test its resilience.
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
Smart Medical Devices Market to Grow at 17.1% CAGR Through 2030
Boston, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, "Smart Medical Devices: Global Markets" is projected to grow from $87.7 billion in 2025 to $193.3 billion by the end of 2030, at a compound annual growth rate ( CAGR ) of 17.1% from 2025 through 2030.
Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds
- Invests in 100th Portfolio Company, Celebrates 25th Year of Franchise Operation - - Announces Promotion of Lauren Flickinger and Ben Scruggs, Ph.D., as Partners -
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
3 Reasons Growth Investors Will Love Boston Scientific ( BSX )
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
VEEV's strong first quarter, product innovations and strategic deals drive growth prospects despite rising costs.
CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls
Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
EXAS Stock Dips Despite Q2 Earnings & Revenue Beat, '25 Sales View Up
Exact Sciences tops on Q2 earnings and revenue estimates and raises the 2025 outlook, but shares slide 8% after results.
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
J&J's MedTech Unit Sales Improve in Q2: Will the Upside Continue?
Johnson & Johnson's Q2 MedTech sales beat estimates, fueled by cardiovascular gains, surgical vision growth and new product momentum.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bruker's Q2 Earnings Miss Estimates, Stock Tumbles, Margins Contract
BRKR's Q2 profit drops sharply, revenues decrease, and weak demand leads to guidance cuts despite cost-saving plans.
What's Going On With Boston Scientific Stock Friday? - Boston Scientific ( NYSE:BSX )
Boston Scientific linked 386 injuries and 16 deaths to calcified defibrillator leads. The FDA is reviewing the high-risk issue tied to shock delivery failures in ePTFE-coated leads. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session this Sunday. Register Now →
Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y
INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.
AMN Stock Slips Despite Q2 Earnings & Revenue Beat, Margins Down
AMN Healthcare tops second-quarter 2025 earnings and revenue forecasts, but margins and segment sales face continued pressure.
Solventum Stock Gains on Q2 Earnings & Revenue Beat, Margins Improve
SOLV jumps 5% as Q2 earnings and revenues beat estimates. EPS outlook raised on broad-based segment growth.
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock
Abbott outpaces market trends as EPD sales surge, fueled by double-digit growth, biosimilar approvals and strong product demand.
TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.
XRAY Stock Rises on Q2 Earnings & Revenues Beat, Adjusted Margins Up
DENTSPLY SIRONA tops Q2 earnings estimates with margin gains, but revenue declines and U.S. weakness persists.
BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up
BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up
Zimmer Biomet gains as Q2 earnings and revenues top estimates. full-year EPS guidance raised on strong segment growth.
Investors Heavily Search Boston Scientific Corporation ( BSX ) : Here is What You Need to Know
Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View
McKesson beats on Q1 earnings and raises FY26 EPS view, but shares slip as gross margin narrows and spin-off plans weigh on investors' sentiment.
STE Beats on Q1 Earnings and Revenues, Raises '26 Sales View
STERIS posts 15% EPS growth and raises FY26 revenue outlook, with all segments showing solid year-over-year gains.
ACB Stock Down as Q1 Earnings Miss Estimates, Revenues Up Y/Y
Aurora Cannabis stock slips after Q1 earnings miss, but revenue climbs 17.5% year over year on strong global medical cannabis demand.
Avanos Medical Stock Down as Q2 Earnings Miss Estimates, Margins Down
AVNS shares dip 12% as Q2 earnings miss estimates, margins shrink, and tariff pressures weigh on profitability.
QuidelOrtho Stock Gains Following Q2 Earnings Beat, Margins Expand
QDEL stock rises 12.8% after Q2 earnings beat. Adjusted margins improve amid soft revenue and ongoing business headwinds.
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.
MASI Stock Slips Despite Q2 Earnings and Revenue Beat, Margins Expand
Masimo's second-quarter 2025 performance beats earnings and revenue estimates, expands margins and lifts 2025 outlook.
FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y
Fresenius Medical stock rises as Q2 earnings and revenues top estimates, driven by solid organic growth and expanding margins.
CLOV Q2 Earnings In Line, Stock Falls on Raised Insurance BER View
Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised
Cencora posts strong Q3 results with earnings and revenues surpassing estimates. raises FY25 EPS guidance on robust U.S. segment growth.
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls
TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.
ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors
EINDHOVEN, The Netherlands, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- ONWARD Medical N.V. ( Euronext: ONWD and US OTCQX: ONWRY ) , the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury ( SCI ) and other movement ...
ONWARD Medical Announces the Appointment of Lucas Buchanan to its Board of Directors - ONWARD MED NV SP/ADR by Onward Med NV ( OTC:ONWRY )
Buchanan is former CFO and COO of Silk Road Medical, where he successfully scaled a growth-stage medical device company, leading to an acquisition by Boston Scientific.
Edwards Lifesciences ( EW ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, July 24, 2025, at 5 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
